Logo image of DMN

DAMON INC (DMN) Stock Fundamental Analysis

USA - NASDAQ:DMN - CA2357501063 - Common Stock

0.0017 USD
-0.01 (-77.33%)
Last: 5/19/2025, 7:59:52 PM
0.0017 USD
0 (0%)
After Hours: 5/19/2025, 7:59:52 PM
Fundamental Rating

0

Taking everything into account, DMN scores 0 out of 10 in our fundamental rating. DMN was compared to 37 industry peers in the Automobiles industry. DMN may be in some trouble as it scores bad on both profitability and health. DMN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DMN has reported negative net income.
DMN Yearly Net Income VS EBIT VS OCF VS FCFDMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 1M -1M 2M 3M 4M

1.2 Ratios

DMN has a Return On Assets (-8.32%) which is in line with its industry peers.
Industry RankSector Rank
ROA -8.32%
ROE N/A
ROIC N/A
ROA(3y)-41.98%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMN Yearly ROA, ROE, ROICDMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 75.61%, DMN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DMN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMN Yearly Profit, Operating, Gross MarginsDMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 500 1K

More info and screens

0

2. Health

2.1 Basic Checks

DMN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DMN remains at a similar level compared to 1 year ago.
Compared to 1 year ago, DMN has a worse debt to assets ratio.
DMN Yearly Shares OutstandingDMN Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M 20M
DMN Yearly Total Debt VS Total AssetsDMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 500K 1M 1.5M

2.2 Solvency

DMN has an Altman-Z score of -10.82. This is a bad value and indicates that DMN is not financially healthy and even has some risk of bankruptcy.
DMN has a Altman-Z score of -10.82. This is in the lower half of the industry: DMN underperforms 74.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.82
ROIC/WACCN/A
WACC8.51%
DMN Yearly LT Debt VS Equity VS FCFDMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 500K 1M 1.5M

2.3 Liquidity

A Current Ratio of 0.11 indicates that DMN may have some problems paying its short term obligations.
The Current ratio of DMN (0.11) is worse than 89.74% of its industry peers.
A Quick Ratio of 0.11 indicates that DMN may have some problems paying its short term obligations.
DMN has a Quick ratio of 0.11. This is amonst the worse of the industry: DMN underperforms 84.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
DMN Yearly Current Assets VS Current LiabilitesDMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 500K 1M 1.5M

More info and screens

0

3. Growth

3.1 Past

DMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1702.78%.
DMN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.09%.
EPS 1Y (TTM)-1702.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-14.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DMN Yearly Revenue VS EstimatesDMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 100K 200K 300K 400K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DMN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMN Price Earnings VS Forward Price EarningsDMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMN Per share dataDMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAMON INC

NASDAQ:DMN (5/19/2025, 7:59:52 PM)

After market: 0.0017 0 (0%)

0.0017

-0.01 (-77.33%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)05-27 2025-05-27
Earnings (Next)N/A N/A
Inst Owners1.34%
Inst Owner Change-77.35%
Ins Owners7.76%
Ins Owner Change0%
Market Cap4.17M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.38
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.32%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.61%
FCFM N/A
ROA(3y)-41.98%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -10.82
F-ScoreN/A
WACC8.51%
ROIC/WACCN/A
Cap/Depr(3y)138.1%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1702.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.09%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-128.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-75.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.43%
OCF growth 3YN/A
OCF growth 5YN/A